Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.49 ^USD	+4.97%		+3.58%	-14.88%

Apr. 16	Foghorn Therapeutics Names Kristian Humer CFO	MT
Apr. 16	Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	CI

Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 07, 2024 at 07:09 am EST

Foghorn Therapeutics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 98.43 million compared to USD 108.88 million a year ago. Basic loss per share from continuing operations was USD 2.34 compared to USD 2.62 a year ago.

Latest news about Foghorn Therapeutics Inc.

Foghorn Therapeutics Names Kristian Humer CFO	Apr. 16	MT
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	Apr. 16	CI
Transcript : Foghorn Therapeutics Inc. - Special Call	Apr. 09
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	Mar. 05	CI
Eli Lilly: Foghorn's anti-tumor drug selected for clinical development	Feb. 08	CF
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product	Feb. 08	DJ
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	Feb. 08	CI
Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024	Jan. 17	CI
Foghorn Therapeutics Inc. Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	Jan. 08	CI
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	Jan. 05	MT
Foghorn Therapeutics Says CFO is Leaving; Shares Fall After-Hours	Jan. 03	MT
Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024	Jan. 03	CI
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $6 From $10, Maintains Equalweight Rating	Nov. 13	MT
Foghorn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Foghorn Therapeutics Inc. to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference	23-10-04	CI
Foghorn Therapeutics Begins Phase 1 Combination Study of FHD-286 to Treat AML	23-08-31	MT
Foghorn Therapeutics Inc. Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed And/Or Refractory AML	23-08-31	CI
Insider Sell: Foghorn Therapeutics	23-08-18	MT
Foghorn Therapeutics Inc Announces Executive Changes	23-08-08	CI
Foghorn Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Pfizer, Flagship Pioneering to invest $100 mln in drug discovery	23-07-18	RE
Pfizer, Flagship Pioneering to invest $100 mln for drug discovery	23-07-18	RE
Morgan Stanley Adjusts Price Target on Foghorn Therapeutics to $10 From $13, Maintains Equal-Weight Rating	23-07-06	MT

Chart Foghorn Therapeutics Inc.

Duration

Period

More charts

Company Profile

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Companyâs Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Foghorn Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.49 USD

Average target price

13.75 USD

Spread / Average Target

+150.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FOGHORN THERAPEUTICS INC.	-14.88%	234M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs